ANI Pharmaceuticals, Inc. (ANIP)
| Market Cap | 1.78B |
| Revenue (ttm) | 883.37M |
| Net Income (ttm) | 70.22M |
| Shares Out | 22.75M |
| EPS (ttm) | 3.32 |
| PE Ratio | 23.59 |
| Forward PE | 8.64 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 118,419 |
| Open | 80.19 |
| Previous Close | 79.60 |
| Day's Range | 78.32 - 81.01 |
| 52-Week Range | 56.71 - 99.50 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 110.00 (+40.24%) |
| Earnings Date | May 8, 2026 |
About ANIP
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, gr... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for ANIP stock is "Strong Buy." The 12-month stock price target is $110.0, which is an increase of 40.24% from the latest price.
News
ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its first quarter 2026 financial results...
ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity
PRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets i...
ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules
PRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg ...
ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet
PRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administrati...
ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology
PRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced publication of the results from the NEW DAY clinical trial involving I...
ANI Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Rare Disease assets now drive 60% of revenue, with Cortrophin and ILUVIEN showing strong growth and long-term durability due to large underpenetrated markets and patent protection. Generics and Brands provide cash flow for reinvestment, while expanded sales teams and strategic initiatives support continued momentum.
ANI Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026
Strong 2025 results and robust 2026 guidance highlight rare disease as the main growth driver, with Cortrophin Gel expansion and a new sales force targeting acute gouty arthritis. ILUVIEN's growth is supported by new data and label expansion, while operating leverage is expected in 2027.
ANI Pharmaceuticals Transcript: 47th Annual Raymond James Institutional Investor Conference
The company projects over $1 billion in 2026 sales, with rare disease driving 60% of revenue and Cortrophin Gel as the lead growth asset. Generics continue to deliver strong cash flow, funding expansion and clinical initiatives, while financial strength supports ongoing transformation.
ANI Pharmaceuticals Turns Profit, Rare Disease Sales Surge 50%
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) shares are down early Friday following the company's strong fourth-quarter report.
ANI Pharmaceuticals Earnings Call Transcript: Q4 2025
Record 2025 results with 44% revenue growth and 47% adjusted EBITDA growth, led by rare disease and generics. 2026 guidance targets over $1B in revenue, with Cortrophin Gel and generics as key drivers and significant investments in sales force expansion and clinical evidence generation.
ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance
PRINCETON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the fourth quarter and ye...
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
PRINCETON, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, along with ...
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET
PRINCETON, N.J., Feb. 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its fourth quarter and full year 2025 fin...
ANI Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rare disease is set to drive over 60% of 2026 revenues, led by Purified Cortrophin Gel’s 55%-65% growth and a major expansion into acute gouty arthritis. Generics remain a strong cash generator, funding rare disease investments, while Iluvien’s growth is targeted through new commercial strategies and access initiatives.
ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities
For full year 2025, total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS expected to be within or above guidance ranges of $854 million to $873 million, $221 million to $228...
ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will present at the 4...
ANI Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference
Rare disease and generics drive strong growth, with 2025 revenue and EBITDA guidance up over 39% and 42% respectively. Cortrophin Gel sees broad uptake, especially in new indications and via prefilled syringes, while ILUVIEN and generics benefit from focused commercial and R&D strategies.
ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise
Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists ...
ANI Pharmaceuticals Announces Board Transition
Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025
The business is experiencing strong growth driven by rare disease assets, especially Cortrophin Gel, which targets large, underpenetrated patient populations. Expanded Salesforce, clinical evidence, and new product formats are fueling adoption, while ILUVIEN is positioned for growth after a reset year.
ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir...
ANI Pharmaceuticals Earnings Call Transcript: Q3 2025
Record Q3 results with 54% revenue growth and nearly doubled Cortrophin Gel sales. 2025 guidance raised for revenue, EBITDA, and EPS, with Rare Disease and Generics driving performance. ILUVIEN faces near-term headwinds but long-term growth expected.
ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance
Record quarterly net revenues of $227.8 million, an increase of 53.6% year-over-year Purified Cortrophin® Gel net revenues of $101.9 million, an increase of 93.8% year-over-year Record quarterly adjus...
ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results ...